Europe
For the first time in Europe, a pegylated G-CSF biosimilar pegfilgrastim will be available to patients for the treatment of neutropenia
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
AstraZeneca and its MedImmune division released data on overall survival (OS) in its Phase III PACIFIC clinical trial of Imfinzi (durvalumab).
Swiss pharmaceutical giant Novartis plans to slash approximately 2,200 jobs in Switzerland over the next four years.
TCT18: BIONYX Study Shows Strong Performance with Durable Polymer Resolute Onyx DES in Head-to-Head Comparison with Biodegradable Polymer DES
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
Abingworth today announced that Brian Gallagher, PhD, will join Abingworth as a Partner based in the company’s Boston office.
InflaRx N.V. announced today that Jens Holstein has been appointed as a new board member of InflaRx, serving as Non-Executive Director.
Cinfa Biotech today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorization for Pelmeg® (B12019)
Here’s a look at who’s making moves in the biotech and pharma world this week.
PRESS RELEASES